BioWorld

Feb. 25, 2005

Pfizer Buys More, Gains Caspase Inhibitors Through Idun Purchase

Although it had plenty of money in the bank, Idun Pharmaceuticals Inc. made a strategic decision to become part of a big pharmaceutical company that will help advance its lead liver disease product. (BioWorld Today) Read More

Analyst: Pharma Returns To Antibodies, At Times Too Late

Pharsight Software Used For FDA's Critical Path Initiative

Agreement Brings Prolexys Antitumor Compound Rights

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...